David Jaworski has been appointed director of Lachman Consultants Compliance Practice.
 
Mr. Jawaorski joins the company from the FDA where he most recently served as acting branch chief of the Domestic Compliance Branch, Division of Domestic Drug Quality (DDDQ) in the Office of Manufacturing and Product Quality (OMPQ)/Office of Compliance/CDER. In this position, he was responsible for the management, review, approval and resolution of recommended enforcement actions based on violation of GMP requirements and standards for product quality and data integrity. He was also a member of the Drug Shortage Investigation team and helped develop some of the approaches to resolving drug shortages, and was actively involved in the scientific and regulatory evaluation and development of policy and requirements for parenteral and PET drugs.
 
Mr. Jawaorski previously served the FDA as team leader for the Domestic Compliance Manufacturing Branch (DCMB), Acting Branch Chief for the International Compliance Branch and Case Officer, DCMB. Prior to the FDA, he worked in the pharmaceutical industry for more than 30 years and held management positions at various companies including IVAX, Sandoz, Bristol-Myers, Abbott and William H. Rorer, Inc.